Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome.

Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Aloush A, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ.

Am J Transplant. 2005 Aug;5(8):2022-30.

2.

The significance of a single episode of minimal acute rejection after lung transplantation.

Hachem RR, Khalifah AP, Chakinala MM, Yusen RD, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP, Walter MJ.

Transplantation. 2005 Nov 27;80(10):1406-13.

PMID:
16340783
3.

Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.

Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J.

J Heart Lung Transplant. 1998 Dec;17(12):1255-63.

PMID:
9883768
4.

Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.

Valentine VG, Gupta MR, Walker JE Jr, Seoane L, Bonvillain RW, Lombard GA, Weill D, Dhillon GS.

J Heart Lung Transplant. 2009 Feb;28(2):163-9. doi: 10.1016/j.healun.2008.11.907.

PMID:
19201342
5.

Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.

Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA.

Am J Respir Crit Care Med. 2008 May 1;177(9):1033-40. doi: 10.1164/rccm.200706-951OC. Epub 2008 Feb 8.

PMID:
18263803
6.

Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation.

Luckraz H, Sharples L, McNeil K, Wreghitt T, Wallwork J.

J Heart Lung Transplant. 2003 Mar;22(3):287-91.

PMID:
12633696
7.

Risk factors for the development of obliterative bronchiolitis after lung transplantation.

Girgis RE, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, Ting A, Johnstone I, Miller J, Robbins RC, Reitz BA, Theodore J.

J Heart Lung Transplant. 1996 Dec;15(12):1200-8.

PMID:
8981205
8.

Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation.

Bando K, Paradis IL, Komatsu K, Konishi H, Matsushima M, Keena RJ, Hardesty RL, Armitage JM, Griffith BP.

J Thorac Cardiovasc Surg. 1995 Jan;109(1):49-57; discussion 57-9.

9.

Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.

Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC.

Transplantation. 2003 Jun 27;75(12):2064-8.

PMID:
12829913
10.

HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction.

Girnita AL, Duquesnoy R, Yousem SA, Iacono AT, Corcoran TE, Buzoianu M, Johnson B, Spichty KJ, Dauber JH, Burckart G, Griffith BP, McCurry KR, Zeevi A.

Am J Transplant. 2005 Jan;5(1):131-8.

11.

Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?

Neurohr C, Huppmann P, Leuchte H, Schwaiblmair M, Bittmann I, Jaeger G, Hatz R, Frey L, Uberfuhr P, Reichart B, Behr J; Munich Lung Transplant Group.

Am J Transplant. 2005 Dec;5(12):2982-91.

12.

Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group.

Sundaresan S, Trulock EP, Mohanakumar T, Cooper JD, Patterson GA.

Ann Thorac Surg. 1995 Nov;60(5):1341-6; discussion 1346-7.

PMID:
8526624
13.

Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.

Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen NL.

Transplantation. 2002 Sep 27;74(6):799-804.

PMID:
12364858
14.

Long-term outcome of lung transplantation is predicted by the number of HLA-DR mismatches.

van den Berg JW, Hepkema BG, Geertsma A, Koëter GH, Postma DS, de Boer WJ, Lems SP, van der Bij W.

Transplantation. 2001 Feb 15;71(3):368-73.

PMID:
11233895
15.

Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome.

Burton CM, Carlsen J, Mortensen J, Andersen CB, Milman N, Iversen M.

J Heart Lung Transplant. 2007 Jul;26(7):681-6.

PMID:
17613397
16.

Bronchiolitis obliterans syndrome development in lung transplantation patients.

Parada MT, Alba A, Sepúlveda C.

Transplant Proc. 2010 Jan-Feb;42(1):331-2. doi: 10.1016/j.transproceed.2009.11.037.

PMID:
20172344
17.

Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?

Burton CM, Iversen M, Mortensen J, Carlsen J, Andersen CB, Milman N, Scheike T.

J Heart Lung Transplant. 2007 Nov;26(11):1127-34. Epub 2007 Sep 29.

PMID:
18022078
18.

HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome.

Sundaresan S, Mohanakumar T, Smith MA, Trulock EP, Lynch J, Phelan D, Cooper JD, Patterson GA.

Transplantation. 1998 Mar 15;65(5):648-53.

PMID:
9521198
19.

Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.

Burton CM, Iversen M, Carlsen J, Mortensen J, Andersen CB, Steinbrüchel D, Scheike T.

J Heart Lung Transplant. 2009 Sep;28(9):888-93. doi: 10.1016/j.healun.2009.04.022.

PMID:
19716040
20.

Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.

Ailawadi G, Smith PW, Oka T, Wang H, Kozower BD, Daniel TM, Kron IL, Jones DR.

J Thorac Cardiovasc Surg. 2008 Mar;135(3):594-602. doi: 10.1016/j.jtcvs.2007.10.044. Epub 2008 Jan 18.

Supplemental Content

Support Center